Evidence map›Paper›PMID 40591237›Full record

ReviewJournal of applied genetics2025

Design principle of successful genome editing applications using CRISPR-based toolkits.

Juhi Sharma, Rajesh Biswas, Prashant Khare

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of applied genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Juhi SharmaXenesis, Absolute, 5 th Floor,Plot 68, Sector 44, Haryana, 122003, Gurugram, India.
Rajesh BiswasXenesis, Absolute, 5 th Floor,Plot 68, Sector 44, Haryana, 122003, Gurugram, India.
Prashant KhareXenesis, Absolute, 5 th Floor,Plot 68, Sector 44, Haryana, 122003, Gurugram, India. prashant@xenesis.bio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are the most promising toolkit of synthetic biology for genetic engineering applications across species. Essentially, the Type II CRISPR system, featuring Cas9 nuclease from Streptococcus pyogenes complexed with sgRNA, introduces targeted DNA cleavage, enabling modifications with exceptional precision. This technology can be utilized for not only editing but also modulating gene expressions, thereby finding widespread utility in various biotechnological applications. Here we discuss strategies to construct a consolidated platform aiming at developing a CRISPR-based gene editing system in microbial hosts such as yeast. Employing the well-known gene editing enzymes, i.e., Cpf1 and dCas9, two independent strategies to develop a one-pot plasmid system have been proposed. Furthermore, approaches to reduce off-target cleavages introduced by non-specific targeting of CRISPR complex have been discussed. Finally, an overarching discussion on advanced strategies to design robust CRISPR components is provided for streamlining future genome editing applications.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsGene EditingGenetic EngineeringPlasmidsRNA, Guide, CRISPR-Cas SystemsStreptococcus pyogenesSynthetic BiologyRNA, Guide, CRISPR-Cas SystemsChIP-SeqCRISPR/Cas9CRISPR/Cpf1CRISPR/dCas9DISCOVER-SeqExpression regulationGenetic engineeringGUIDE-SeqOff-target effectsWhole genome sequencingYeast

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.